CPHI China 2026 Drug Development and Technology Innovation Conference – Two Special Forums on in-vivo CAR-T & mRNA Will Be Held in Shanghai!

In 2017, Dr. Wang became the founding president of Fosun Kite, leading his team to implement the technology of Yikida, produce and register it for clinical use within three years, making it the first CAR-T product approved by the Chinese FDA. In 2021, he founded Xingyiong Biotech, developing iPSC-derived general-purpose, mass-produced, tumor- and autoimmune disease-treating dual-platform CAR-iNK/CAR-iT cell therapy products, with early products already in clinical validation stage.

Dr. Wang has published dozens of scientific papers and monographs throughout his career and obtained multiple national invention patent authorizations. He also holds social positions such as Vice President of the Cell Therapy Research and Application Society of the Chinese Society of Cell Biology and Deputy Chairperson of the CGT Committee of the Shanghai Biomedical Association. He has received honors such as Pudong Pearl Plan Entrepreneurship Leadership Talent and Shanghai White Orchid Memorial Award.

Dr. Zhu Yuchao, Co-founder & General Manager of HanXin Biotech, is a Suzhou Gusu Leading Talent and Park Leading Talent. He has authorized or accepted more than ten patents. In 2024, he was named a Young Influencer in the China Biopharmaceutical Industry Innovation List U45, Vice Chairperson of the CBIITA Consortium Cell Therapy Committee, and planner and host of the SAPA China 2025 Cell Therapy Forum. With over 10 years of biopharmaceutical industrialization experience, he helped establish and transfer technology for the first sterile formulation factory in China at Eli Lilly. He also contributed to the launch of China’s first CAR-T cell therapy product and the successful launch of China’s first overseas PD-1 drug.

Dr. Zhou Guoqing obtained his Ph.D. in molecular biology from Sweden and has worked as a research scientist in Canada and the US, accumulating solid academic and research foundations. He has over 20 years of experience in new drug research and focuses on the transformation and industrialization of innovative therapies.

Dr. Zhou is a serial entrepreneur who founded and sold two biotech companies. He has held key leadership positions such as CEO, Chief Science Officer, and Chairman in enterprises, possessing rich strategic and operational management experience. He also served as Chief Operating Officer of SiBiono GeneTech, participating in the development of the world’s first viral gene therapy drug "Gendicine" based on adenovirus vectors expressing p53 gene, which is milestone in gene therapy.

With a deep background across academia and industry, Dr. Zhou invented the new treatment method of in-vivo CAR-Tumor with engineered in-vivo cancer cells and is committed to promoting biological technology innovation and clinical translation, facilitating the application of cutting-edge research results in real medical practice.

Dr. Chen Limo studied and worked at Harvard University and Anderson Cancer Center from 2005 to 2021, receiving 16 important awards. Based on his discovery of new CD38 functions, global pharmaceutical companies have developed several new drugs. In 2024, he founded Queenboat Pharmaceuticals, whose development was reported by CCTV. He was invited to the Xinhua News Agency studio to provide insights for the series report "Confidence of the Chinese Economy" from a pharmaceutical industry perspective, with key parts published on Xinhua Net. He is a Top 10 Innovator of the New Era in 2024, Responsible Business Leader of 2024, Shaping the Future Person of the CCTV Era in 2025, and a think tank expert of the China Future Research Association. His company was awarded the "National Brand. Shining World" Key Promotion Brand and Excellent Case of Private Enterprise Technology Innovation.

Ms. Li Qian is the Executive Director of Frost & Sullivan China’s medical team, specializing in cell immunotherapy industry. She has extensive knowledge and experience in IPO industry consulting, new product market access, and pricing. She actively participates in corporate investment and financing plans, achieving corporate growth through industry chain resource integration, park implementation, and external promotion, accumulating rich industry experience.

Mr. Yang Haitao is a Ph.D. in Medical Genetics from Uppsala University in Sweden, a postdoctoral fellow in Tumor Genetics and Neurogenetics at University of California, San Francisco/Los Angeles, and a researcher in Rheumatology at the School of Medicine, University of California, San Diego. After returning to China, he became a Qianjiang Scholar Distinguished Professor and a researcher at Sun Yat-sen University Shenzhen Research Institute. Currently, he is an industry professor at Southern University of Science and Technology’s Cell and Gene Therapy Research Center. He is the founder of RemiOna (Guangzhou) Biopharmaceutical Technology Co., Ltd., having long been involved in tumor genomics, tumor mRNA vaccines, and RNA large model research.

Dr. Zhang Weiguo is the R&D VP at Renjing Biotech, leading the establishment of mRNA purification and multiple analysis methods, responsible for the company’s mRNA technology platform, pipeline expansion, and early research. He is a "Mass Innovation" talent in Jiangsu Province, PI of the "Unveiled Challenge and Leadership" project of the National Innovation Center for Cell Therapy and a key technical project PI in Suzhou. Previously, he was an assistant professor at Lawrence Berkeley National Laboratory and a postdoctoral fellow at University of California, Berkeley, and a Ph.D. in genetics from Iowa State University.

Mr. Fei Caiyi graduated with a Ph.D. in Biological Information Science from Zhejiang University of Science and Technology, under Professor Liu Haiyan. He has many years of research experience in molecular dynamics simulation and high-throughput sequencing, and has successfully developed multiple clinical high-throughput sequencing analysis platforms. He has published multiple papers in journals such as science advance and npj vaccines and obtained multiple invention patent authorizations. As co-founder of Chengshi Biotech, he is responsible for identifying, optimizing, and conducting clinical research on mRNA drug targets. He led his team to develop platforms for systematic identification of cross-species immune epitopes,体液 immune antigen design, and mRNA sequence optimization.